China Pharma (CPHI) vs Marker Therapeutics (MRKR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Marker Therapeutics (MRKR) has outperformed China Pharma (CPHI) over the past year, gaining 2.8% versus a loss of 72.6%. Over five years, MRKR leads with a -91.1% price change compared with -99.8% for CPHI. China Pharma is the larger company by market cap ($18.9 million vs $18.2 million), about 1.0 times the size.
China Pharma converts more of its revenue into profit, with a net margin of -76.9% versus -343.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | MRKR |
|---|---|---|
| Share price | $0.4384 | $1.09 |
| Market cap | $18.86M | $18.17M |
| 1-day change | -13.00% | -17.42% |
| YTD return | -63.77% | -26.85% |
| 1-year return | -72.60% | +2.83% |
| 5-year return | -99.84% | -91.14% |
| EPS (TTM) | $-0.42 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.14M | $3.55M |
| Revenue growth (YoY) | -8.49% | -46.19% |
| Net income (latest FY) | $-3.19M | $-12.16M |
| Gross margin | -3.18% | — |
| Operating margin | -78.16% | -363.45% |
| Net margin | -76.91% | -342.96% |
| 52-week high | $19.19 | $2.46 |
| 52-week low | $0.38 | $0.81 |
| Distance from 52-week high | -97.72% | -55.69% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +622.02% |
| Average volume | 1.60M | 711.96K |
| Shares outstanding | 43.02M | 16.67M |
| Employees | 215 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRKR has outperformed CPHI by 75.4 percentage points over the past year.
- China Pharma is more profitable, keeping -76.9 cents of every revenue dollar as net income versus -343.0 cents for Marker Therapeutics.
- China Pharma grew revenue faster in its latest fiscal year (-8.49% vs -46.19%).
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees
About Marker Therapeutics
MRKR stock →Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CPHI vs MRKR FAQ
Which is bigger, China Pharma or Marker Therapeutics?
China Pharma (CPHI) is larger, with a market capitalization of $18.86M compared with $18.17M for Marker Therapeutics (MRKR).
Which stock has performed better over the past year, CPHI or MRKR?
MRKR returned +2.83% over the past 12 months, compared with -72.60% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and Marker Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.